Overview
Materialise Q3 revenue beats analyst expectations despite a 3.5% yr/yr decline
Adjusted EBITDA for Q3 misses analyst estimates
Materialise Medical segment revenue grows 10.3% yr/yr, setting a quarterly record
Outlook
Materialise expects 2025 revenue between 265,000k EUR and 280,000k EUR
Company maintains 2025 Adjusted EBIT guidance of 6,000k EUR to 10,000k EUR
Materialise cites geopolitical volatility impacting business environment
Result Drivers
MEDICAL SEGMENT GROWTH - Materialise Medical segment revenue increased 10.3% yr/yr, setting a quarterly record
MANUFACTURING SEGMENT DECLINE - Materialise Manufacturing segment revenue decreased 17.1% yr/yr due to macro-economic headwinds
COST CONTROL MEASURES - Company implemented targeted cost control measures to protect operational profitability
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | EUR 66.25 mln | EUR 65.10 mln (2 Analysts) |
Q3 EPS | EUR 0.03 | ||
Q3 Net Income | EUR 1.84 mln | ||
Q3 Adjusted EBITDA | Miss | EUR 8.42 mln | EUR 10 mln (1 Analyst) |
Q3 Gross Profit | EUR 37.65 mln | ||
Q3 Operating Income | EUR 2.52 mln | ||
Q3 Pretax Profit | EUR 2.40 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy"
Wall Street's median 12-month price target for Materialise NV is $8.50, about 30.1% above its October 27 closing price of $5.94
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 26 three months ago
Press Release: ID:nBw1NyrkGa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)